Cormorant Asset Management’s Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 OTLKW Stock Holding History

Cormorant Asset Management’s Portfolio OTLKW Stock Details OTLKW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-270,698	Closed	-$32K	–	86
2021 Q4	$32K	Hold	270,698	–	–	﹤0.01%	78
2021 Q3	$54K	Sell	270,698 -145,968	-35%	-$39.6K	﹤0.01%	88
2021 Q2	$130K	Hold	416,666	–	–	﹤0.01%	104
2021 Q1	$421K	Buy	+416,666	New	+$322K	0.01%	118
2020 Q4	–	Sell	-416,666	Closed	-$54K	–	113
2020 Q3	$54K	Hold	416,666	–	–	﹤0.01%	93
2020 Q2	$117K	Hold	416,666	–	–	﹤0.01%	81
2020 Q1	$65K	Hold	416,666	–	–	﹤0.01%	73
2019 Q4	$27K	Hold	416,666	–	–	﹤0.01%	67
2019 Q3	$50K	Hold	416,666	–	–	﹤0.01%	74
2019 Q2	$46K	Hold	416,666	–	–	﹤0.01%	70
2019 Q1	$150K	Hold	416,666	–	–	0.01%	63
2018 Q4	$64K	Buy	+416,666	New	+$52.5K	0.01%	69

Cormorant Asset Management's OTLKW Position: Q1 2022 in Review

Cormorant Asset Management sold out of Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 (OTLKW) in Q1 2022, closing a stake of 270,698 shares — an estimated $32K sold.

Cormorant Asset Management first reported a position in OTLKW in Q4 2018 and held it in 12 quarters. The position peaked at $421K in Q1 2021. 0 funds tracked by Wall St. Rank hold OTLKW as of Q1 2022.

Cormorant Asset Management reported no remaining Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 position as of Q1 2022 after selling out during the quarter.
Cormorant Asset Management sold 270,698 Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 shares in Q1 2022, an estimated $32K.
Cormorant Asset Management first reported a position in Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 in Q4 2018 and held it in 12 quarters.
Cormorant Asset Management's Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 position peaked at $421K in Q1 2021.
0 funds tracked by Wall St. Rank held Outlook Therapeutics, Inc. Series A Warrant Expiring 02/18/2022 as of Q1 2022.

Based on Cormorant Asset Management's 13F filing for Q1 2022, filed 16 May 2022.